DGAP-News

Fresenius Medical Care AG & Co. KGaA reports strong third quarter and confirms full year guidance

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Quarter
Results
Fresenius Medical Care AG & Co. KGaA reports strong third quarter and
confirms full year guidance

27.10.2016 / 07:04
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Fresenius Medical Care reports strong third quarter and confirms
full year guidance

- Group revenue +9% (+9% at constant currency), driven by a strong
performance in Health Care services

- EBIT growth in line with revenue growth, supported by very good
development in Latin America and Asia-Pacific

- Significant net income growth of 27% (+17% excluding special items)

- Care Coordination with positive growth momentum (revenue +29%) and
improved sequential margin of 5% (+60 basis points) in line with
expectations

- Full year 2016 guidance confirmed

Key figures - third quarter and first nine months 2016:

$ million Q3 2016 Q3 2015 Growth yoy 9m 2016 9m 2015 Growth yoy
Net revenue 4,598 4,231 +9% 13,224 12,390 +7%
Operating income (EBIT) 670 614 +9% 1,851 1,665 +11%
Net income 333 262 +27% 855 713 +20%
Net income (excl. special items) 333 284 +17% 855 735 +16%
Basic earnings per share (in $) 1.09 0.86 +26% 2.80 2.34 +19%

"We are very pleased with our performance in the third quarter of 2016,
which is the result of a strong execution in all regions, the success of
our Global Efficiency Program as well as further expansion of our global
footprint," said Rice Powell, Chief Executive Officer of Fresenius Medical
Care. "Care Coordination services maintain excellent growth momentum which
will help us to extend our range of health care services even further.
Based on our strong result for the third quarter, we hereby confirm our
guidance for the full-year 2016."

Revenue & earnings
Net revenue for the third quarter improved by 9% and reached $4,598 million
(+9% at constant currency), mainly driven by a strong performance in Health
Care services. Contributing revenues of $3,734 (+10%), Health Care services
was largely supported by an improvement in US revenue per treatment (+$3)
as well as a strong organic growth. Dialysis products revenue increased by
4% to $864 million in the third quarter, mainly driven by higher sales of
machines, dialyzers and products for acute care.

Net revenue in the first nine months of 2016 increased by 7% (Health Care
services revenue +8%/+9% at constant currency; dialysis products revenue
+2%/+4% at constant currency).
In the third quarter, operating income (EBIT) increased by 9% to $670
million, in line with revenue growth. The operating income margin increased